Jun. 16 at 12:46 AM
$CLDX Celldex announces data on barzolvolimab from its Phase 2 trial in CSU
Celldex Therapeutics announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria, CSU. The data were presented today by Dr. Martin Metz in an oral presentation at the European Academy of Allergy and Clinical Immunology, EAACI, Congress 2025.
Celldex previously announced that the Phase 2 study in CSU met its primary and secondary endpoints at 12 weeks with clinically meaningful and statistically significant decreases in UAS7 compared to placebo across multiple dose groups, including improvements in quality of life and angioedema measurements, and demonstrated a favorable safety profile.
The data presented further support these results by demonstrating improvements in AAS7 and additional measures of angioedema control over the 52 week treatment period. AAS7 measures the frequency and intensity of angioedema episodes, where higher scores indicate increased angioedema activity.
